Genor Biopharma Holdings Limited (HK:6998) has released an update.
Genor Biopharma Holdings Limited has announced a delay in dispatching its circular related to a major proposed merger and other corporate changes. The extension, granted to finalize necessary details and reviews, pushes the deadline to February 28, 2025. Investors are advised to remain cautious as the merger’s completion depends on several regulatory approvals.
For further insights into HK:6998 stock, check out TipRanks’ Stock Analysis page.